OVEMP in Myasthenia
NCT03049956 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96
Last updated 2021-01-11
Summary
Myasthenia gravis is an autoimmune disorder of neuromuscular transmission, characterized by fluctuating muscle weakness and fatigability. In isolated ocular myasthenia, when only the extraocular muscles are involved, most common ancillary tests, such as acetylcholine receptor autoantibodies and repetitive nerve stimulation, are often negative.
A simple, quick and non-invasive test for ocular myasthenia based on ocular vestibular evoked myogenic potentials (oVEMP) was recently developed.
The main goal of the study is to validate repetitive oVEMP stimulation in a blinded diagnostic accuracy study in order to facilitate early and accurate diagnosis of ocular myasthenia.
Conditions
- Myasthenia Gravis, Ocular
Interventions
- DIAGNOSTIC_TEST
-
Ocular vestibular evoced myogenic potentials
The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
Sponsors & Collaborators
-
University of Zurich
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-11-01
- Primary Completion
- 2020-12-31
Countries
- Switzerland
Study Locations
More Related Trials
-
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
NCT03896295 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
NCT06298552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT06381284 ·Status: COMPLETED
-
A Prospective Cohort Study Of Myasthenia Gravis
NCT04674605 ·Status: UNKNOWN
-
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Prednisone In the Treatment of Ocular Myasthenia
NCT00995722 ·Status: TERMINATED ·Phase: PHASE3
-
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
NCT07033559 ·Status: NOT_YET_RECRUITING
-
Meningococcal Vaccination in Patients on Complement Inhibitors
NCT06906692 ·Status: ACTIVE_NOT_RECRUITING
-
The Evaluation of Belimumab in Myasthenia Gravis (MG)
NCT01480596 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
NCT03052751 ·Status: COMPLETED ·Phase: PHASE2
-
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
NCT06002945 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT02965573 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
NCT04980495 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT00727194 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
NCT03863080 ·Status: COMPLETED ·Phase: PHASE2
-
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
NCT07146425 ·Status: RECRUITING
-
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
NCT00424489 ·Status: TERMINATED ·Phase: PHASE1
-
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT06617741 ·Status: RECRUITING
-
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
NCT02950155 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical and Laboratory Profile of Myasthenia Gravis in Children At Sohag University Hospitals
NCT06774937 ·Status: NOT_YET_RECRUITING